Developer docs
API playgroundTry for free, no card

Search company profiles

Tetris Pharma

Full company profile

uuid0031imw

Namestring
Tetris Pharma
Legal namestring
Tetris Pharma Ltd
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Tetris Pharma was a UK-based niche specialty pharmaceutical company that operated from its founding in 2020 until formally ceasing operations on 1st October 2025. The company was registered as Tetris Pharma Ltd (registration number 12548259) and headquartered at Chesterford Research Park in Little Chesterford, Saffron Walden, UK. Its stated strategic intent was to build a European platform for marketing a range of prescription pharmaceutical products.

The company commercialized a single core product, Ogluo, a prescription pharmaceutical indicated for diabetes management. It served two primary customer segments on a horizontal basis: end-user patients requiring access to Ogluo, and healthcare professionals (HCPs) who prescribed or recommended the product. The firm employed between 11 and 50 staff and operated as a privately-held limited company throughout its existence, with leadership including Leslie Galloway (Chairman) and Maddy Kennedy (CFO). No public funding rounds, acquisitions, AI/ML capabilities, or proprietary technology disclosures are present in the available data, consistent with a pure commercial rather than R&D-driven specialty pharma business.

Effective 1st October 2025, Tetris Pharma formally ceased operations. All outstanding matters, medical information requests, product complaints, adverse event reporting, and general enquiries have been transferred to Arecor Therapeutics, which now serves as the residual handler for Ogluo-related business and patient/HCP communications. The company website at tetrispharma.com directs all stakeholders to Arecor's contact channels.

Short descriptiontext

Tetris Pharma was a UK-based specialty pharmaceutical company that commercialized Ogluo, a single prescription diabetes product, to patients and healthcare professionals before ceasing operations on 1st October 2025.

Operating statusenum
Closed
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMarlow, United Kingdom
HQ citystring
Marlow
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, prescription medicines, diabetes medication, pharmaceutical marketing, European pharma platform
Industry2 codes
PRIMARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals
No data
Cost components4 values
Supply Chain, Marketing or Sales, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Tetris Pharma was a UK-based niche specialty pharmaceutical company that built a European platform to market prescription products, primarily commercializing Ogluo, a pharmaceutical product for diabetes management aimed at patients and healthcare professionals. The company ceased operations effective 1st October 2025, with outstanding matters handled by Arecor Therapeutics.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Tetris Pharma operated as a single-product pharmaceutical company offering Ogluo, a medication available to both patients and healthcare professionals. The company formally ceased operations effective October 1, 2025, with medical information, product complaints, and adverse event reporting managed through contact channels listed on their website.

Product and service1 record
1Ogluo
CategorySpecialty Pharmaceuticals / Diabetes Medication
Description

Ogluo is a prescription pharmaceutical product for diabetes management, marketed by Tetris Pharma to patients and healthcare professionals. The company formally ceased operations on 1st October 2025, with outstanding matters referred to Arecor Therapeutics.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Arecor Therapeutics
Strategic tierCoreTypeOthersAnnounced on2025-10-01
Description

Following Tetris Pharma's cessation of operations effective 1st October 2025, Arecor Therapeutics has taken over handling of all outstanding matters, enquiries, medical information requests, and other business matters previously managed by Tetris Pharma. Contact: info@arecor.com or +44(0)1223 426060.

tetrispharma.com
Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Peers10 records
1Zealand Pharma
TypeDirect peer
Description

Danish specialty biopharmaceutical company that developed and commercialised Zegalogue (dasiglucagon), a glucagon rescue product for severe hypoglycemia in diabetes — directly comparable to Tetris Pharma's marketed product Ogluo in therapeutic indication, mechanism and patient segment.

2Novo Nordisk
TypeBroad incumbent
Description

Global diabetes incumbent selling the full range of insulin and glucagon products (including the GlucaGen glucagon rescue line) across Europe and globally — directly competitive with Tetris in the severe-hypoglycemia rescue category, but operating at vastly greater scale and breadth.

3Eli Lilly
TypeBroad incumbent
Description

Major diabetes franchise operator with insulin offerings and historical presence in glucagon rescue — overlaps with Tetris Pharma in the diabetes/endocrinology prescribing audience served by Ogluo across European markets.

4Sanofi
TypeBroad incumbent
Description

Global diabetes incumbent with broad insulin and glucose-rescue portfolios, competing for the same European HCP and patient audiences that Tetris targeted with Ogluo.

5Xeris Biopharma
TypeDirect peer
Description

US specialty biopharma that developed and commercialised Gvoke, a ready-to-use glucagon rescue product for severe hypoglycemia — a direct competitor to Ogluo in mechanism, indication and prescriber audience.

6Arecor Therapeutics
TypeOthers
Description

UK-based specialty pharmaceutical formulation company now formally responsible for handling Tetris Pharma's outstanding matters, medical information and adverse-event reporting — directly linked as the successor/transition counterparty and itself a UK specialty pharma peer.

7Chiesi Farmaceutici
TypeRegional player
Description

European-headquartered specialty pharmaceutical company marketing prescription products across multiple therapeutic areas including endocrinology — comparable to Tetris Pharma's model of building a European commercial platform for prescription products.

8Recordati
TypeRegional player
Description

European specialty pharmaceutical group commercialising prescription products across endocrinology and rare-disease categories — comparable to Tetris as a European-focused specialty pharma commercial platform.

9Norgine
TypeRegional player
Description

European specialty pharmaceutical company marketing prescription products across the UK and continental Europe — a comparable European-focused specialty pharma commercial model to the platform Tetris was building.

10Shield Therapeutics
TypeEmerging player
Description

UK-listed specialty pharmaceutical company commercialising prescription products in focused therapeutic areas — comparable in scale, UK base and specialty-pharma commercial model to Tetris Pharma.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Tetris Pharma

Specialty Pharmaceuticalstetrispharma.com

Tetris Pharma was a UK-based specialty pharmaceutical company that commercialized Ogluo, a single prescription diabetes product, to patients and healthcare professionals before ceasing operations on 1st October 2025.

What Tetris Pharma does

Tetris Pharma was a UK-based niche specialty pharmaceutical company that operated from its founding in 2020 until formally ceasing operations on 1st October 2025. The company was registered as Tetris Pharma Ltd (registration number 12548259) and headquartered at Chesterford Research Park in Little Chesterford, Saffron Walden, UK. Its stated strategic intent was to build a European platform for marketing a range of prescription pharmaceutical products.

The company commercialized a single core product, Ogluo, a prescription pharmaceutical indicated for diabetes management. It served two primary customer segments on a horizontal basis: end-user patients requiring access to Ogluo, and healthcare professionals (HCPs) who prescribed or recommended the product. The firm employed between 11 and 50 staff and operated as a privately-held limited company throughout its existence, with leadership including Leslie Galloway (Chairman) and Maddy Kennedy (CFO). No public funding rounds, acquisitions, AI/ML capabilities, or proprietary technology disclosures are present in the available data, consistent with a pure commercial rather than R&D-driven specialty pharma business.

Effective 1st October 2025, Tetris Pharma formally ceased operations. All outstanding matters, medical information requests, product complaints, adverse event reporting, and general enquiries have been transferred to Arecor Therapeutics, which now serves as the residual handler for Ogluo-related business and patient/HCP communications. The company website at tetrispharma.com directs all stakeholders to Arecor's contact channels.

Tetris Pharma firmographics

Firmographics
Name
Tetris Pharma
Legal name
Tetris Pharma Ltd
Website
https://tetrispharma.com
Company type
Private
Founded year
2020
Operating status
Closed
Headcount range
11–50 employees
Short description
Tetris Pharma was a UK-based specialty pharmaceutical company that commercialized Ogluo, a single prescription diabetes product, to patients and healthcare professionals before ceasing operations on 1st October 2025.
Ownership category
akta.pro rank

Tetris Pharma industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Specialty pharmaceuticals
  • Prescription medicines
  • Diabetes medication
  • Pharmaceutical marketing
  • European pharma platform

Where Tetris Pharma is headquartered

Location

Headquarters

HQ city
Marlow
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Tetris Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Marketing or Sales, Personnel, Operations

Tetris Pharma product offering

Product offering

Core offering

Tetris Pharma was a UK-based niche specialty pharmaceutical company that built a European platform to market prescription products, primarily commercializing Ogluo, a pharmaceutical product for diabetes management aimed at patients and healthcare professionals. The company ceased operations effective 1st October 2025, with outstanding matters handled by Arecor Therapeutics.

Product overview

Tetris Pharma operated as a single-product pharmaceutical company offering Ogluo, a medication available to both patients and healthcare professionals. The company formally ceased operations effective October 1, 2025, with medical information, product complaints, and adverse event reporting managed through contact channels listed on their website.

Differentiator

Problem solved

Functional benefit

Products and services

  • Ogluo Ogluo is a prescription pharmaceutical product for diabetes management, marketed by Tetris Pharma to patients and healthcare professionals. The company formally ceased operations on 1st October 2025, with outstanding matters referred to Arecor Therapeutics.

Companies that use Tetris Pharma

Customer profile

Segments2 records

Ideal customer profiles2 records

Tetris Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Tetris Pharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Arecor TherapeuticscoreOthers · 1 October 2025Following Tetris Pharma's cessation of operations effective 1st October 2025, Arecor Therapeutics has taken over handling of all outstanding matters, enquiries, medical information requests, and other business matters previously managed by Tetris Pharma. Contact: info@arecor.com or +44(0)1223 426060.

Scale indicators1 record

Recent moves3 records

Tetris Pharma competitors and assessment

Company assessment

Direct peers

  • Zealand Pharma: Danish specialty biopharmaceutical company that developed and commercialised Zegalogue (dasiglucagon), a glucagon rescue product for severe hypoglycemia in diabetes — directly comparable to Tetris Pharma's marketed product Ogluo in therapeutic indication, mechanism and patient segment.
  • Xeris Biopharma: US specialty biopharma that developed and commercialised Gvoke, a ready-to-use glucagon rescue product for severe hypoglycemia — a direct competitor to Ogluo in mechanism, indication and prescriber audience.

Broad incumbents

  • Novo Nordisk: Global diabetes incumbent selling the full range of insulin and glucagon products (including the GlucaGen glucagon rescue line) across Europe and globally — directly competitive with Tetris in the severe-hypoglycemia rescue category, but operating at vastly greater scale and breadth.
  • Eli Lilly: Major diabetes franchise operator with insulin offerings and historical presence in glucagon rescue — overlaps with Tetris Pharma in the diabetes/endocrinology prescribing audience served by Ogluo across European markets.
  • Sanofi: Global diabetes incumbent with broad insulin and glucose-rescue portfolios, competing for the same European HCP and patient audiences that Tetris targeted with Ogluo.

Others

  • Arecor Therapeutics: UK-based specialty pharmaceutical formulation company now formally responsible for handling Tetris Pharma's outstanding matters, medical information and adverse-event reporting — directly linked as the successor/transition counterparty and itself a UK specialty pharma peer.

Regional players

  • Chiesi Farmaceutici: European-headquartered specialty pharmaceutical company marketing prescription products across multiple therapeutic areas including endocrinology — comparable to Tetris Pharma's model of building a European commercial platform for prescription products.
  • Recordati: European specialty pharmaceutical group commercialising prescription products across endocrinology and rare-disease categories — comparable to Tetris as a European-focused specialty pharma commercial platform.
  • Norgine: European specialty pharmaceutical company marketing prescription products across the UK and continental Europe — a comparable European-focused specialty pharma commercial model to the platform Tetris was building.

Emerging players

  • Shield Therapeutics: UK-listed specialty pharmaceutical company commercialising prescription products in focused therapeutic areas — comparable in scale, UK base and specialty-pharma commercial model to Tetris Pharma.

Market position

Strengths1 record

Weaknesses3 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

Tetris Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Tetris Pharma leadership team

Management profile

Number of profiles

Profiles2 records

Tetris Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Tetris Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tetris Pharma

What does Tetris Pharma do?

Tetris Pharma was a UK-based niche specialty pharmaceutical company that built a European platform to market prescription products, primarily commercializing Ogluo, a pharmaceutical product for diabetes management aimed at patients and healthcare professionals. The company ceased operations effective 1st October 2025, with outstanding matters handled by Arecor Therapeutics.

Is Tetris Pharma a public or private company?

Tetris Pharma is a private company. It is classified as unknown and is currently closed.

When was Tetris Pharma founded?

Tetris Pharma was founded in 2020. It employs 11 to 50 people.

Where is Tetris Pharma based?

Tetris Pharma is headquartered in Marlow, United Kingdom, in the Europe region.

Who are Tetris Pharma's main competitors?

Direct peers on record are Zealand Pharma and Xeris Biopharma. Broad incumbents are Novo Nordisk, Eli Lilly and Sanofi. Arecor Therapeutics is listed as an others. Regional players are Chiesi Farmaceutici, Recordati and Norgine. Shield Therapeutics is listed as an emerging player.

Does Tetris Pharma have an API?

No public API is recorded for Tetris Pharma.

What industry is Tetris Pharma in?

Tetris Pharma's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health), with a secondary code of HLAIAAAA, Primary Care & General Medicine Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarketScreenerArecor Therapeutics subsidiary Tetris Pharma signs deal with GoodlifeTetris Pharma signed an exclusive commercialization agreement with Goodlife to import, market, and distribute Ogluo in the BeNeLux region. The Dutch healthcare company will launch the glucagon autoinjector in the Netherlands in the first half of 2024. Arecor Therapeutics shares rose 1.7% to 193.15 pence on Monday.GlobeNewswireTetris Pharma signs service agreement with Syneos HealthTetris Pharma signed a service agreement with Syneos Health to support the commercial roll-out of Ogluo, a glucagon autoinjector for diabetes, across Europe. The partnership will provide outsourced contract sales services to accelerate practitioner awareness. The company had recently launched Ogluo in Germany.Business Wire BlogXeris’ Commercialization Partner for Ogluo®, Tetris Pharma Ltd, to Be Acquired by Arecor TherapeuticsArecor Therapeutics has agreed to acquire Tetris Pharma Ltd, contingent upon a successful capital offering by Arecor. This transaction ensures that Tetris will continue its role as the commercialization partner for Xeris Biopharma's Ogluo product in the UK and EEA. The acquisition represents a strategic transition of commercial responsibilities within the biopharmaceutical sector.Xeris Biopharma HoldingsXeris Pharmaceuticals Enters Into an Exclusive License and Supply Agreement with Tetris Pharma Limited to Commercialize Ogluo® in EuropeXeris Pharmaceuticals and Tetris Pharma signed an exclusive license and supply agreement to commercialize Ogluo in Europe, with Xeris supplying and Tetris marketing. The deal includes up to $71 million in time- and milestone-based payments plus royalties, and a first UK launch is expected in Q4 2021.BenzingaXeris Pharma, Tetris Ink Commercialization Pact For Ogluo In Europe - Xeris Biopharma Holdings (NASDAQ:XEXeris Pharmaceuticals Inc has entered into an exclusive agreement with Tetris Pharma Limited to commercialize Ogluo, a treatment for severe hypoglycemia, across the European Economic Area, U.K., and Switzerland. Under the terms, Xeris will receive up to $71 million in milestone payments and royalties on net sales, while Tetris takes responsibility for commercialization in the territory. The company plans to launch in the U.K. by the end of 2021 and expand to at least seven additional countries by mid-2022, targeting a market of over five million insulin-dependent patients at risk of severe hypoglycemia.